Literature DB >> 35443826

The Role of Immune Regulatory Molecules in COVID-19.

Zahra Khalifehzadeh-Esfahani1, Soheila Fattahi2, Zahra Heidari Haratemeh3, Morteza Jafarinia4.   

Abstract

As the fifth pandemic in the 21st century, coronavirus 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the most prominent global concern in the last 2 years. Variable manifestations characterize SARS-CoV-2 infection. Despite the design and production of effective vaccines and their considerable effect on reducing the COVID-19 prevalence and mortality rate, no definitive cure for the disease has yet been found. Mutations may also affect the effectiveness of vaccines. The host immune response to the pathogen has a critical role in the course of the disease. Positive and negative signals often balance the immune system. Immune regulatory molecules, also known as immune checkpoint receptors, balance the immune responses. These molecules mainly have inhibitory functions and prevent hyperactivation of immune cells or trigger adverse signaling pathways. For a decade, the immune checkpoint blockade, as a therapeutic target for cancer immunotherapy, has been utilized. Some of the inhibitory receptors are recognized as exhaustion markers on T cells. The signaling pathway of these markers restricts the function of T cells against viral infection. Dysregulation of T cells was observed in SARS-CoV-2 infection and can modify proliferation, differentiation, cytokine production, and type of response. The pivotal role of immune inhibitory receptors in the function of acquired, cell-mediated, immune defense T cells makes them a fascinating subject to study. This review article summarized recent findings on immune regulatory molecules and their role in SARS-CoV-2 infection, hoping to find a way to design novel treatments.

Entities:  

Keywords:  BTLA; COVID-19; CTLA-4; GITR; PD-1; SARS-CoV-2; TIM-3

Mesh:

Year:  2022        PMID: 35443826     DOI: 10.1089/vim.2021.0211

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.175


  1 in total

1.  Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study.

Authors:  Borja Quiroga; María José Soler; Alberto Ortiz; Carlos Jesús Jaravaca Mantecón; Nathasha Nava Pérez; Marta Serra Martín; Yurika Sato; Antonio José Marin Franco; Diana Flor Pazmiño Zambrano; Rafael Lucena Valverde; Mayra Ortega Diaz; Carmen Calderón González; Juan Manuel Cazorla López; Mónica Pereira; Emilio González Parra; Ana Sánchez Horrillo; Carmen Sánchez González; Néstor Toapanta; Secundino Cigarrán Guldris; Rosa Sánchez Hernández; Soledad Pizarro Sánchez; María Muñiz Rincón; Nuria Garcia-Fernández; Natalia Blanco Castro; Rocío Collantes Mateo; Manuel Augusto Quiroz Morales; Beatriz Escamilla-Cabrera; Isabel Berdud Godoy; Beatriz Gil-Casares Casanova; Alba Leyva; José Rojas; Ron T Gansevoort; Patricia de Sequera
Journal:  Clin Kidney J       Date:  2022-07-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.